


**Claims:**

1. A method for reducing inflammation in a subject, the method comprising administering an anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I



(I)

or a pharmaceutically acceptable salt thereof to the subject in need of such treatment.

2. The method of claim 1 wherein the pharmaceutically acceptable salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I is an acid addition salt.
3. The method of claim 1 wherein the pharmaceutically acceptable salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I is a monomethanesulfonate salt.
4. A method of claim 1, 2 or 3, wherein the inflammation involves monocytes.
5. The method of claim 4 wherein the inflammation involves macrophage colony stimulating factor (M-CSF)-stimulated monocytes
6. The method of claim 4 wherein the inflammation is involved in conditions selected from the group consisting of autoimmune diseases, arthritis, and lung injuries.
7. The method of claim 1 wherein the inflammation is chronic.
8. The method of claim 1 wherein the inflammation is acute.

9. The method of claim 1 wherein the subject is a mammal.
10. The method of claim 9 wherein the subject is a human subject.
11. The method of claim 1, 2, or 3 wherein the anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or pharmaceutically acceptable salt thereof is in the range from 10 mg to 1000 mg.
12. The method of claim 11 wherein the anti-inflammatory effective amount is in the range from 50 mg to 600 mg.
13. 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I, or a pharmaceutically acceptable salt thereof, for use in treatment of inflammation.
14. 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I for the treatment of chronic inflammation.
15. 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I for the treatment of acute inflammation.
16. Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use in the treatment of inflammation.
17. Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use in the treatment of chronic inflammation.
18. Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use in the treatment of acute inflammation.
19. The use according to claim 16, wherein the inflammation involves monocytes.
20. The use according to claim 16 wherein the inflammation involves macrophage stimulating factor (M-CSF)-stimulated monocytes.

21. The use according to claim 16 wherein the inflammation is related to autoimmune diseases, arthritis, or lung injuries.
22. The use according to claim 16 wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I is an acid addition salt.
23. The use according to claim 16 wherein the 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I is a monomethanesulfonate salt.
24. The use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for suppressing the differentiation of monocytes.
26. The use according to claim 24 wherein the medicament is used *in vitro*.
27. The use according to claim 24 wherein the medicament is used *in vivo*.